Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib

ClinicalTrials.gov ID: NCT00474786

Public ClinicalTrials.gov record NCT00474786. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 7, 2026, 12:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized Trial Of Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced Renal Cell Carcinoma Who Have Failed First-Line Sunitinib Therapy

Study identification

NCT ID
NCT00474786
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Pfizer
Industry
Enrollment
512 participants

Conditions and interventions

Interventions

  • Sorafenib Drug
  • temsirolimus (Torisel) Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 31, 2007
Primary completion
Dec 31, 2011
Completion
Dec 31, 2012
Last update posted
Nov 20, 2013

2007 – 2013

United States locations

U.S. sites
26
U.S. states
13
U.S. cities
22
Facility City State ZIP Site status
Pfizer Investigational Site Duarte California 91010
Pfizer Investigational Site La Jolla California 92037
Pfizer Investigational Site La Jolla California 92093
Pfizer Investigational Site Los Angeles California 90095-6984
Pfizer Investigational Site Los Angeles California 90095
Pfizer Investigational Site Orange California 92868
Pfizer Investigational Site Riverside California 92505
Pfizer Investigational Site San Diego California 92103
Pfizer Investigational Site Meriden Connecticut 06451
Pfizer Investigational Site Municie Indiana 47303
Pfizer Investigational Site Louisville Kentucky 40202
Pfizer Investigational Site Metairie Louisiana 70006
Pfizer Investigational Site Baltimore Maryland 21201
Pfizer Investigational Site Bethesda Maryland 20817
Pfizer Investigational Site Tupelo Mississippi 38801
Pfizer Investigational Site New York New York 10065
Pfizer Investigational Site Cleveland Ohio 44195
Pfizer Investigational Site Oklahoma City Oklahoma 73120
Pfizer Investigational Site Tulsa Oklahoma 74104
Pfizer Investigational Site Austin Texas 78731
Pfizer Investigational Site Dallas Texas 75226
Pfizer Investigational Site Dallas Texas 75246
Pfizer Investigational Site San Antonio Texas 78229
Pfizer Investigational Site Salt Lake City Utah 84112-5550
Pfizer Investigational Site Salt Lake City Utah 84412
Pfizer Investigational Site Seattle Washington 98101

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 102 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00474786, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 20, 2013 · Synced May 7, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00474786 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →